Danaher Corporation (DHR)

Danaher's stock price has decreased by 23.53% between June 24, 2024, and June 23, 2025, with a price of $196.39 as of June 20, 2025. In Q1 2025, Danaher exceeded earnings and revenue expectations, with bioprocessing performing strongly. Analysts issued various ratings, including Barclays maintaining an "Overweight" rating and Stifel upgrading to "Buy." Recent announcements include SCIEX and Evosep expanding access to standardized proteomics and Danaher announcing a diagnostic development partnership. Insiders and members of Congress have sold DHR stock. The last dividend payment was $0.32 per share on April 25, 2025.

Danaher Corporation is generally not subject to material seasonality. However, some businesses experience seasonal trends related to their industries. European sales are weaker in the summer, while medical and capital equipment sales are stronger in the fourth quarter. A slower start to the respiratory season was a headwind for Q1 2025. Demand is influenced by customer budgets, government funding, interest rates, and economic cycles.

Danaher Corporation is a global science and technology conglomerate that designs, manufactures, and markets products and services for professional, medical, industrial, and commercial applications. It operates in the Life Science Tools & Diagnostics sector and is involved in CROs. Danaher's business is structured around Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides tools and services for therapeutics development. The Life Sciences segment offers research tools for studying genes, proteins, and cells. The Diagnostics segment provides instruments, reagents, and services for disease diagnosis. The Environmental & Applied Solutions segment was spun off into Veralto Corporation in Q4 2023.

Danaher Corporation has a global presence, operating in over 60 countries and 700 locations. Manufacturing facilities are in North America, Europe, Asia, and Latin America. Sales are through independent distributors and direct sales. In 2017, North America accounted for 40% of sales, Europe 28%, Asia/Australia 24%, and other regions 8%. More recently, North America accounts for 35.5%, Europe 29%, Asia-Pacific 24.2%, and Emerging Markets 11.3%. Digital platforms reach 92 countries, generating $3.2 billion in digital sales in 2023.

Danaher is considered a top pick in the Life Science Tools & Diagnostics sector, recognized for its bioprocessing and diagnostics performance, and cost management. It was listed among Forbes' "Most Trusted Companies in America (2025)" and "America's Best Companies (2025)" in Engineering, Manufacturing. Analysts see Danaher as a long-term compounder that can navigate cyclical issues. Potential risks include negative publicity from recalls, product liability claims, or studies on medical device safety.

Danaher Corporation's ownership includes institutional, retail, and individual investors. Institutional investors hold 47.21% to 78.63% of the stock. Insiders own 8.78% to 25.72%, and public companies and individual investors hold 18.65% to 25.36%. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., and State Street Corp. The largest individual shareholders are Steven M. Rales, owning 13.01%, and Mitchell P. Rales, owning 11.86%.